Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI South East AsiaCPhI South East Asia
Not Confirmed
Not Confirmed
16-18 July, 2025
Specialty & Agro Chemi...Specialty & Agro Chemical
Not Confirmed
Not Confirmed
29 June-01 July, 2025
Discovery EuropeDiscovery Europe
Not Confirmed
Not Confirmed
01-02 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI South East AsiaCPhI South East Asia
Industry Trade Show
Not Confirmed
16-18 July, 2025
Specialty & Agro Chemi...Specialty & Agro Chemical
Industry Trade Show
Not Confirmed
29 June-01 July, 2025
Discovery EuropeDiscovery Europe
Industry Trade Show
Not Confirmed
01-02 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/j-j-s-intra-cellular-buyout-bms-oncology-gambit-sanofi-s-blueprint-acquisition-drive-mega-deals-in-h1-2025
20 Jun 2025
// CONTRACTPHARMA
https://www.contractpharma.com/breaking-news/ferring-opens-new-gene-therapy-manufacturing-facility/
05 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250505375419/en/Ferring-Presents-New-Phase-3b-Safety-and-Effectiveness-Data-for-Recurrent-C.-Diff-Patients-Receiving-REBYOTA-fecal-microbiota-live-jslm-Via-Colonoscopy-and-Additional-Analyses-at-DDW
24 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250424910916/en/U.S.-FDA-Approves-Second-Drug-Product-Manufacturing-Facility-for-ADSTILADRIN-nadofaragene-firadenovec-vncg
21 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250421675994/en/Ferring-Announces-Initial-Data-from-Phase-3-Trial-in-Japanese-Patients-Demonstrating-75-Complete-Response-Rate-at-3-Months-with-nadofaragene-firadenovec-in-BCG-unresponsive-NMIBC-Patients1
21 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250421677477/en/Ferring-Unveils-New-Data-with-ADSTILADRIN-nadofaragene-firadenovec-vncg-at-112th-Annual-Meeting-of-the-Japanese-Urological-Association
15 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/bladder-cancer-advocacy-network-announces-national-presenting-sponsorships-by-ferring-pharmaceuticals-and-the-astellaspfizer-alliance-for-the-2025-walks-to-end-bladder-cancer-302429261.html
Details:
Adstiladrin (nadofaragene firadenovec) is an intravesical non-replicating gene therapy for adult patients with high-risk BCG-unresponsive NMIBC with CIS with or without papillary tumors.
Lead Product(s): Nadofaragene Firadenovec
Therapeutic Area: Oncology Brand Name: Adstiladrin
Study Phase: Approved FDFProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 21, 2025
Lead Product(s) : Nadofaragene Firadenovec
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ferring Shows 75% Response at 3 Months in NMIBC Phase 3 Trial in Japan
Details : Adstiladrin (nadofaragene firadenovec) is an intravesical non-replicating gene therapy for adult patients with high-risk BCG-unresponsive NMIBC with CIS with or without papillary tumors.
Product Name : Adstiladrin
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 21, 2025
Details:
Adstiladrin (nadofaragene firadenovec) is the first FDA-approved intravesical gene therapy for high-risk BCG-unresponsive NMIBC with carcinoma in situ, evaluated for adult patients.
Lead Product(s): Nadofaragene Firadenovec
Therapeutic Area: Oncology Brand Name: Adstiladrin
Study Phase: Approved FDFProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 16, 2024
Lead Product(s) : Nadofaragene Firadenovec
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ferring Adds Three New Studies to Bladder Cancer Program for ADSTILADRIN®
Details : Adstiladrin (nadofaragene firadenovec) is the first FDA-approved intravesical gene therapy for high-risk BCG-unresponsive NMIBC with carcinoma in situ, evaluated for adult patients.
Product Name : Adstiladrin
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 16, 2024
Details:
Adstiladrin (nadofaragene firadenovec-vncg) is an FDA-approved gene therapy delivering a human IFNα2b gene to the bladder for treating BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): Nadofaragene Firadenovec
Therapeutic Area: Oncology Brand Name: Adstiladrin
Study Phase: Phase IVProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 24, 2024
Phase 4 Study Evaluates ADSTILADRIN® Use in Real-World Setting
Details : Adstiladrin (nadofaragene firadenovec-vncg) is an FDA-approved gene therapy delivering a human IFNα2b gene to the bladder for treating BCG-unresponsive non-muscle invasive bladder cancer.
Product Name : Adstiladrin
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 24, 2024
Details:
ADSTILADRIN® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical gene therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): Nadofaragene Firadenovec
Therapeutic Area: Oncology Brand Name: Adstiladrin
Study Phase: Approved FDFProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 09, 2023
Lead Product(s) : Nadofaragene Firadenovec
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADSTILADRIN® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical gene therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
Product Name : Adstiladrin
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 09, 2023
Details:
Adstiladrin (nadofaragene firadenovec-vncg) is the first and only FDA-approved non-replicating adenovirus vector-based therapy for the treatment of adult patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors.
Lead Product(s): Nadofaragene Firadenovec
Therapeutic Area: Oncology Brand Name: Adstiladrin
Study Phase: Approved FDFProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 06, 2023
Lead Product(s) : Nadofaragene Firadenovec
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Adstiladrin (nadofaragene firadenovec-vncg) is the first and only FDA-approved non-replicating adenovirus vector-based therapy for the treatment of adult patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillar...
Product Name : Adstiladrin
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 06, 2023
Details:
Under the agreement, Royalty Pharma is acquiring a 5.1 percentage royalty on net sales of Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy developed as a treatment for adult patients with BCG-unresponsive NMIBC, in the United States.
Lead Product(s): Nadofaragene Firadenovec
Therapeutic Area: Oncology Brand Name: Adstiladrin
Study Phase: Approved FDFProduct Type: Cell and Gene therapy
Sponsor: Royalty Pharma
Deal Size: $500.0 million Upfront Cash: $300.0 million
Deal Type: Agreement August 23, 2023
Lead Product(s) : Nadofaragene Firadenovec
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Royalty Pharma
Deal Size : $500.0 million
Deal Type : Agreement
Details : Under the agreement, Royalty Pharma is acquiring a 5.1 percentage royalty on net sales of Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy developed as a treatment for adult patients with BCG-unresponsive NMIBC, in the United States.
Product Name : Adstiladrin
Product Type : Cell and Gene therapy
Upfront Cash : $300.0 million
August 23, 2023
Details:
SI-6603 (condoliase), which contains Condoliase as its active pharmaceutical ingredient, is intended to treat lumbar disc herniation via a single, direct intradiscal injection.
Lead Product(s): Condoliase
Therapeutic Area: Musculoskeletal Brand Name: SI-6603
Study Phase: Approved FDFProduct Type: Other Large Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 26, 2023
Lead Product(s) : Condoliase
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SI-6603 (condoliase), which contains Condoliase as its active pharmaceutical ingredient, is intended to treat lumbar disc herniation via a single, direct intradiscal injection.
Product Name : SI-6603
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 26, 2023
Details:
Rekovelle (follitropin delta) is a follicle-stimulating hormone made from recombinant human DNA that is used to promote follicular development in females with ovarian failure, reproduction and fertility.
Lead Product(s): Follitropin Delta
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Rekovelle
Study Phase: Phase IVProduct Type: Hormone
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 14, 2023
Lead Product(s) : Follitropin Delta
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rekovelle (follitropin delta) is a follicle-stimulating hormone made from recombinant human DNA that is used to promote follicular development in females with ovarian failure, reproduction and fertility.
Product Name : Rekovelle
Product Type : Hormone
Upfront Cash : Inapplicable
March 14, 2023
Details:
Rebyota (live fecal microbiota-jslm) is the first and only microbiome-based treatment approved by the U.S. FDA to prevent recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older.
Lead Product(s): Live Fecal Microbiota
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rebyota
Study Phase: Approved FDFProduct Type: Probiotic
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 14, 2023
Lead Product(s) : Live Fecal Microbiota
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ferring Pharmaceuticals Announces Availability of REBYOTA™ (fecal microbiota, live – jslm) –...
Details : Rebyota (live fecal microbiota-jslm) is the first and only microbiome-based treatment approved by the U.S. FDA to prevent recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older.
Product Name : Rebyota
Product Type : Probiotic
Upfront Cash : Inapplicable
February 14, 2023
Details:
Adstiladrin, an intravesical therapy administered every three months, targets the patient’s own bladder wall cells to enhance the body’s natural defenses to fight cancer.
Lead Product(s): Nadofaragene Firadenovec
Therapeutic Area: Oncology Brand Name: Adstiladrin
Study Phase: Approved FDFProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 16, 2022
Lead Product(s) : Nadofaragene Firadenovec
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Approves Ferring Pharma'S First Gene Therapy For Bladder Cancer
Details : Adstiladrin, an intravesical therapy administered every three months, targets the patient’s own bladder wall cells to enhance the body’s natural defenses to fight cancer.
Product Name : Adstiladrin
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 16, 2022
Inspections and registrations
ABOUT THIS PAGE
Ferring Pharmaceuticals is a supplier offers 10 products (APIs, Excipients or Intermediates).
Find a price of Mesalazine bulk with WC offered by Ferring Pharmaceuticals
Find a price of Corticotropin bulk offered by Ferring Pharmaceuticals
Find a price of Desmopressin Acetate bulk offered by Ferring Pharmaceuticals
Find a price of Gonadorelin Acetate bulk offered by Ferring Pharmaceuticals
Find a price of Oxytocin bulk offered by Ferring Pharmaceuticals
Find a price of FACILITIES AND OPERATING PROCEDURES IN WEST GERMANY bulk offered by Ferring Pharmaceuticals
Find a price of FACILITY AND OPERATING PROCEDURES IN MALMO, SWEDEN bulk offered by Ferring Pharmaceuticals
Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN MALMO, SWEDEN. bulk offered by Ferring Pharmaceuticals
Find a price of TRICORTAN (VET MED) bulk offered by Ferring Pharmaceuticals
Find a price of Carbetocin Acetate bulk offered by Ferring Pharmaceuticals